Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Quantitative faecal immunochemical test for patients with ‘high risk’ bowel symptoms: a prospective cohort study

View ORCID ProfileHelga E Laszlo, View ORCID ProfileEdward Seward, View ORCID ProfileRuth M Ayling, View ORCID ProfileJenny Lake, View ORCID ProfileAman Malhi, View ORCID ProfileAllan Hackshaw, View ORCID ProfileClare Stephens, View ORCID ProfileKathy Pritchard-Jones, View ORCID ProfileDonna Chung, View ORCID ProfileMichael Machesney
doi: https://doi.org/10.1101/2020.05.10.20096941
Helga E Laszlo
1North Central London Cancer Alliance
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helga E Laszlo
Edward Seward
1North Central London Cancer Alliance
2University College London Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward Seward
Ruth M Ayling
3Barts Health NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ruth M Ayling
Jenny Lake
3Barts Health NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jenny Lake
Aman Malhi
4Cancer Research UK & UCL Cancer Trials Centre, University College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aman Malhi
Allan Hackshaw
4Cancer Research UK & UCL Cancer Trials Centre, University College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Allan Hackshaw
Clare Stephens
1North Central London Cancer Alliance
5North London Partners in Health and Care
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clare Stephens
Kathy Pritchard-Jones
1North Central London Cancer Alliance
2University College London Hospitals NHS Foundation Trust
6UCL GOS Institute of Child Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kathy Pritchard-Jones
Donna Chung
1North Central London Cancer Alliance
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Donna Chung
Michael Machesney
3Barts Health NHS Trust
7North East London Cancer Alliance
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Machesney
  • For correspondence: Michael.machesney@nhs.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objectives To evaluate whether quantitative measurement of faecal haemoglobin (f-Hb) using faecal immunochemical testing (FIT) can be used to rule out colorectal cancer (CRC) for patients who present to primary care with ‘high risk’ symptoms defined by national guidelines for urgent referral for suspected cancer (NICE NG12).

Design Prospective cohort study carried out between April 2017 and March 2019.

Setting 59 GP practices in London and 24 hospitals in England.

Participants Symptomatic patients in England referred to the urgent CRC pathway who provided a faecal sample for FIT in addition to standard investigations for cancer.

Main outcome measures CRC was confirmed by established clinical and histopathology procedures. f-Hb (μg per gram of stool) was measured in a central laboratory blinded to cancer outcome. We calculated sensitivity (percentage of patients with CRC who have f-Hb exceeding specified cut-offs); false-positive rate [FPR] (percentage of patients without CRC whose f-Hb exceeds the same cut-offs); and positive predictive value [PPV] (percentage of all patients with f-Hb above the cut-offs who have CRC).

Results 4676 patients were recruited of whom 3596 patients were included (had a valid FIT test and a known definitive diagnosis). Among the 3596, median age was 67 years, 53% were female and 78% had colonoscopy. 90 patients were diagnosed with CRC, 7 with other cancers, and 3499 with no cancer found. f-Hb did not correlate with age, sex or ethnicity. Using f-Hb ≥4μg/g (lowest limit of detection), sensitivity, FPR and PPV were 87.8%, 27.0% and 7.7% respectively. Using f-Hb ≥10μg/g, the corresponding measures were 83.3%, 19.9% and 9.7%. 15 patients with CRC had f-Hb below 10μg/g. If FIT had been used at thresholds of 10μg/g or 4μg/g, 1 in 6 or 1 in 8 patients with cancer respectively would have been missed. If the absence of anaemia or abdominal pain is used alongside f-Hb 10 μg/g, only 1 in 18 cancers would be missed but 56% of people without CRC could potentially avoid further investigations including colonoscopies.

Conclusions In our study, if FIT alone had been used to determine urgent referral for patients with ‘high risk’ symptoms for definitive cancer investigation, some patients with bowel cancer would not have been diagnosed. If used in conjunction with clinical features, particularly in the absence of anaemia, the efficacy of FIT is significantly improved. With appropriate safety netting, FIT could be used to focus secondary care diagnostic capacity on patients most at risk of CRC.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was funded by NHS England Cancer Alliance programme (formerly known as the National Cancer Vanguard, part of the New Care Models programme), North London Partners in Health and Care (North Central London’s Sustainability and transformation partnership), NIHR University College London Hospitals Biomedical Research Centre and Cancer Research UK and was conducted independently by the North Central London Cancer Alliance (formerly known as UCLH Cancer Collaborative and North Central and East London Cancer Alliance). The Mast Group provided 2000 FIT test tubes.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Additional summary tables and analyses are available upon request from the senior author, Mr Michael Machesney.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 15, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative faecal immunochemical test for patients with ‘high risk’ bowel symptoms: a prospective cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Quantitative faecal immunochemical test for patients with ‘high risk’ bowel symptoms: a prospective cohort study
Helga E Laszlo, Edward Seward, Ruth M Ayling, Jenny Lake, Aman Malhi, Allan Hackshaw, Clare Stephens, Kathy Pritchard-Jones, Donna Chung, Michael Machesney
medRxiv 2020.05.10.20096941; doi: https://doi.org/10.1101/2020.05.10.20096941
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Quantitative faecal immunochemical test for patients with ‘high risk’ bowel symptoms: a prospective cohort study
Helga E Laszlo, Edward Seward, Ruth M Ayling, Jenny Lake, Aman Malhi, Allan Hackshaw, Clare Stephens, Kathy Pritchard-Jones, Donna Chung, Michael Machesney
medRxiv 2020.05.10.20096941; doi: https://doi.org/10.1101/2020.05.10.20096941

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (433)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8982)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1949)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1328)
  • Health Policy (659)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10800)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1825)
  • Nursing (109)
  • Nutrition (272)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1896)
  • Public and Global Health (4120)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)